## Zhen Lu

## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/6986964/publications.pdf

Version: 2024-02-01

68 6,285 34 66 papers citations h-index g-index

70 70 70 13328

times ranked

citing authors

docs citations

all docs

#	Article	IF	CITATIONS
1	Guidelines for the use and interpretation of assays for monitoring autophagy. Autophagy, 2012, 8, 445-544.	9.1	3,122
2	The tumor suppressor gene ARHI regulates autophagy and tumor dormancy in human ovarian cancer cells. Journal of Clinical Investigation, 2008, 118, 3917-29.	8.2	370
3	Utility of a novel serum tumor biomarker HE4 in patients with endometrioid adenocarcinoma of the uterus. Gynecologic Oncology, 2008, 110, 196-201.	1.4	184
4	Imprinted tumor suppressor genes <i>ARHI</i> and <i>PEG3</i> are the most frequently downâ€regulated in human ovarian cancers by loss of heterozygosity and promoter methylation. Cancer, 2008, 112, 1489-1502.	4.1	149
5	SIK2 Is a Centrosome Kinase Required for Bipolar Mitotic Spindle Formation that Provides a Potential Target for Therapy in Ovarian Cancer. Cancer Cell, 2010, 18, 109-121.	16.8	126
6	Decitabine and suberoylanilide hydroxamic acid (SAHA) inhibit growth of ovarian cancer cell lines and xenografts while inducing expression of imprinted tumor suppressor genes, apoptosis, G2/M arrest, and autophagy. Cancer, 2011, 117, 4424-4438.	4.1	118
7	Potent and Selective Phosphopeptide Mimetic Prodrugs Targeted to the Src Homology 2 (SH2) Domain of Signal Transducer and Activator of Transcription 3. Journal of Medicinal Chemistry, 2011, 54, 3549-3563.	6.4	116
8	The role of biomarkers in the management of epithelial ovarian cancer. Expert Review of Molecular Diagnostics, 2017, 17, 577-591.	3.1	102
9	Prevention and Early Detection of Ovarian Cancer: Mission Impossible?. Recent Results in Cancer Research, 2007, 174, 91-100.	1.8	92
10	Clinically Relevant microRNAs in Ovarian Cancer. Molecular Cancer Research, 2015, 13, 393-401.	3.4	90
11	Dasatinib induces autophagic cell death in human ovarian cancer. Cancer, 2010, 116, 4980-4990.	4.1	77
12	ARHI (DIRAS3) induces autophagy in ovarian cancer cells by downregulating the epidermal growth factor receptor, inhibiting PI3K and Ras/MAP signaling and activating the FOXo3a-mediated induction of Rab7. Cell Death and Differentiation, 2014, 21, 1275-1289.	11.2	67
13	Urinary mesothelin provides greater sensitivity for early stage ovarian cancer than serum mesothelin, urinary hCG free beta subunit and urinary hCG beta core fragment. Gynecologic Oncology, 2007, 106, 490-497.	1.4	65
14	Re-expression of ARHI (DIRAS3) induces autophagy in breast cancer cells and enhances the inhibitory effect of paclitaxel. BMC Cancer, 2011, 11, 22.	2.6	65
15	DIRAS3 regulates the autophagosome initiation complex in dormant ovarian cancer cells. Autophagy, 2014, 10, 1071-1092.	9.1	62
16	Biochemistry and Biology of ARHI (DIRAS3), an Imprinted Tumor Suppressor Gene Whose Expression Is Lost in Ovarian and Breast Cancers. Methods in Enzymology, 2006, 407, 455-468.	1.0	58
17	Multiple histone deacetylases repress tumor suppressor gene ARHI in breast cancer. International Journal of Cancer, 2007, 120, 1664-1668.	5.1	57
18	Expression and epigenetic regulation of angiogenesis-related factors during dormancy and recurrent growth of ovarian carcinoma. Epigenetics, 2013, 8, 1330-1346.	2.7	55

#	Article	IF	CITATIONS
19	A Novel Compound ARN-3236 Inhibits Salt-Inducible Kinase 2 and Sensitizes Ovarian Cancer Cell Lines and Xenografts to Paclitaxel. Clinical Cancer Research, 2017, 23, 1945-1954.	7.0	54
20	Poly(adenosine diphosphate ribose) polymerase inhibitors induce autophagyâ€mediated drug resistance in ovarian cancer cells, xenografts, and patientâ€derived xenograft models. Cancer, 2020, 126, 894-907.	4.1	54
21	Biomarkers and Strategies for Early Detection of Ovarian Cancer. Cancer Epidemiology Biomarkers and Prevention, 2020, 29, 2504-2512.	2.5	53
22	Transcriptional and Posttranscriptional Down-Regulation of the Imprinted Tumor Suppressor Gene ARHI (DRAS3) in Ovarian Cancer. Clinical Cancer Research, 2006, 12, 2404-2413.	7.0	52
23	MUC16 expression during embryogenesis, in adult tissues, and ovarian cancer in the mouse.  Differentiation, 2008, 76, 1081-1092.	1.9	51
24	Loss of the expression of the tumor suppressor gene ARHI is associated with progression of breast cancer. Clinical Cancer Research, 2003, 9, 3660-6.	7.0	51
25	ARHI (DIRAS3)-mediated autophagy-associated cell death enhances chemosensitivity to cisplatin in ovarian cancer cell lines and xenografts. Cell Death and Disease, 2015, 6, e1836-e1836.	6.3	50
26	Modulating Microtubule Stability Enhances the Cytotoxic Response of Cancer Cells to Paclitaxel. Cancer Research, 2011, 71, 5806-5817.	0.9	49
27	Elevation of TP53 Autoantibody Before CA125 in Preclinical Invasive Epithelial Ovarian Cancer. Clinical Cancer Research, 2017, 23, 5912-5922.	7.0	47
28	DIRAS3 (ARHI) Blocks RAS/MAPK Signaling by Binding Directly to RAS and Disrupting RAS Clusters. Cell Reports, 2019, 29, 3448-3459.e6.	6.4	44
29	Tumor necrosis factor- $\hat{l}_{\pm}$ and interferon- $\hat{l}_{3}$ stimulate MUC16 (CA125) expression in breast, endometrial and ovarian cancers through NFκB. Oncotarget, 2016, 7, 14871-14884.	1.8	44
30	RAS-related GTPases <i>DIRAS1</i> and <i>DIRAS2</i> induce autophagic cancer cell death and are required for autophagy in murine ovarian cancer cells. Autophagy, 2018, 14, 637-653.	9.1	43
31	A Ras Homologue Member I Directly Inhibits Signal Transducers and Activators of Transcription 3 Translocation and Activity in Human Breast and Ovarian Cancer Cells. Cancer Research, 2005, 65, 6701-6710.	0.9	42
32	Critical questions in ovarian cancer research and treatment: Report of an American Association for Cancer Research Special Conference. Cancer, 2019, 125, 1963-1972.	4.1	39
33	Validation of a Biomarker Panel and Longitudinal Biomarker Performance for Early Detection of Ovarian Cancer. International Journal of Gynecological Cancer, 2016, 26, 1070-1077.	2.5	36
34	A novel hTERT promoter–driven E1A therapeutic for ovarian cancer. Molecular Cancer Therapeutics, 2009, 8, 2375-2382.	4.1	34
35	Weight Loss Upregulates the Small GTPase DIRAS3 in Human White Adipose Progenitor Cells, Which Negatively Regulates Adipogenesis and Activates Autophagy via Akt–mTOR Inhibition. EBioMedicine, 2016, 6, 149-161.	6.1	34
36	CA125/MUC16 Is Dispensable for Mouse Development and Reproduction. PLoS ONE, 2009, 4, e4675.	2.5	34

#	Article	IF	CITATIONS
37	A phosphopeptide mimetic prodrug targeting the SH2 domain of Stat3 inhibits tumor growth and angiogenesis. Journal of Experimental Therapeutics and Oncology, 2012, 10, 155-62.	0.5	32
38	Paclitaxel Sensitivity of Ovarian Cancer Can be Enhanced by Knocking Down Pairs of Kinases that Regulate MAP4 Phosphorylation and Microtubule Stability. Clinical Cancer Research, 2018, 24, 5072-5084.	7.0	31
39	The tumor suppressor gene <i><i>ARHI&lt;(i)&lt;<i><i><i><i>&gt;(i)&lt;<i><i><i><i><i><i><i>&gt;(i)&lt;<i><i><i><i><i><i><i><i>&gt;(i)&lt;<i><i><i><i><i><i><i><i><i><i><i><i><i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i></i>	2.7	28
40	CDK5 Regulates Paclitaxel Sensitivity in Ovarian Cancer Cells by Modulating AKT Activation, p21Cip1-and p27Kip1-Mediated G1 Cell Cycle Arrest and Apoptosis. PLoS ONE, 2015, 10, e0131833.	2.5	28
41	Anti-HER2 Antibody Trastuzumab Inhibits CDK2-Mediated NPAT and Histone H4 Expression via PI3K Pathway. Cell Cycle, 2006, 5, 1654-1661.	2.6	26
42	The role of vascular endothelial growth factor, interleukin 8, and insulinlike growth factor in sustaining autophagic DIRAS3â€induced dormant ovarian cancer xenografts. Cancer, 2019, 125, 1267-1280.	4.1	26
43	Directed evolution of cyclic peptides for inhibition of autophagy. Chemical Science, 2021, 12, 3526-3543.	7.4	26
44	ARHI (DIRAS3), an imprinted tumour suppressor gene, binds to importins and blocks nuclear import of cargo proteins. Bioscience Reports, 2010, 30, 159-168.	2.4	23
45	Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer. Cancers, 2019, 11, 596.	3.7	22
46	6-Phosphofructo-2-Kinase/Fructose-2,6-Biphosphatase-2 Regulates TP53-Dependent Paclitaxel Sensitivity in Ovarian and Breast Cancers. Clinical Cancer Research, 2019, 25, 5702-5716.	7.0	22
47	Human epididymis protein 4 antigenâ€autoantibody complexes complement cancer antigen 125 for detecting earlyâ€stage ovarian cancer. Cancer, 2020, 126, 725-736.	4.1	21
48	Induction of autophagy by ARHI (DIRAS3) alters fundamental metabolic pathways in ovarian cancer models. BMC Cancer, 2016, 16, 824.	2.6	20
49	Amino Acid Deprivation-Induced Autophagy Requires Upregulation of DIRAS3 through Reduction of E2F1 and E2F4 Transcriptional Repression. Cancers, 2019, 11, 603.	3.7	20
50	DIRAS3: An Imprinted Tumor Suppressor Gene that Regulates RAS and PI3K-driven Cancer Growth, Motility, Autophagy, and Tumor Dormancy. Molecular Cancer Therapeutics, 2022, 21, 25-37.	4.1	20
51	Caspase-3 Substrates for Noninvasive Pharmacodynamic Imaging of Apoptosis by PET/CT. Bioconjugate Chemistry, 2018, 29, 3180-3195.	3 <b>.</b> 6	19
52	SIK2 inhibition enhances PARP inhibitor activity synergistically in ovarian and triple-negative breast cancers. Journal of Clinical Investigation, 2022, 132, .	8.2	17
53	DIRAS3-Derived Peptide Inhibits Autophagy in Ovarian Cancer Cells by Binding to Beclin1. Cancers, 2019, 11, 557.	3.7	16
54	Next steps in the early detection of ovarian cancer. Communications Medicine, 2021, 1, .	4.2	16

#	Article	IF	CITATIONS
55	A MYC-Driven Plasma Polyamine Signature for Early Detection of Ovarian Cancer. Cancers, 2021, 13, 913.	3.7	15
56	NDN is an imprinted tumor suppressor gene that is downregulated in ovarian cancers through genetic and epigenetic mechanisms. Oncotarget, 2016, 7, 3018-3032.	1.8	14
57	SIK2 promotes ovarian cancer cell motility and metastasis by phosphorylating MYLK. Molecular Oncology, 2022, 16, 2558-2574.	4.6	11
58	Elimination of dormant, autophagic ovarian cancer cells and xenografts through enhanced sensitivity to anaplastic lymphoma kinase inhibition. Cancer, 2020, 126, 3579-3592.	4.1	10
59	A Novel Salt Inducible Kinase 2 Inhibitor, ARN-3261, Sensitizes Ovarian Cancer Cell Lines and Xenografts to Carboplatin. Cancers, 2021, 13, 446.	3.7	10
60	Proteome Profiling Uncovers an Autoimmune Response Signature That Reflects Ovarian Cancer Pathogenesis. Cancers, 2020, 12, 485.	3.7	9
61	Nuclear HKII–P-p53 (Ser15) Interaction is a Prognostic Biomarker for Chemoresponsiveness and Glycolytic Regulation in Epithelial Ovarian Cancer. Cancers, 2021, 13, 3399.	3.7	5
62	Adipocyte-like signature in ovarian cancer minimal residual disease identifies metabolic vulnerabilities of tumor initiating cells. JCI Insight, 2021, 6, .	5.0	3
63	Tumor Suppressor Genes. Cancer Treatment and Research, 2009, 149, 109-129.	0.5	3
64	Abstract 2838: TP53 autoantibody can detect CA125 screen negative ovarian cancer cases and can be elevated prior to CA125 in preclinical ovarian cancer. Cancer Research, 2015, 75, 2838-2838.	0.9	3
65	Reply to Comment on "Osteopontin, Macrophage Migration Inhibitory Factor and Anti-Interleukin-8 Autoantibodies Complement CA125 for Detection of Early Stage Ovarian Cancer―Cancers 2019, 11, 596: Markers for Early Detection of Ovarian Cancer. Cancers, 2019, 11, 1386.	3.7	1
66	Abstract 324: SIK2 inhibitors regulate DNA repair pathway and sensitize ovarian cancer to PARP1 inhibitors. , $2018$ , , .		1
67	ARHI (DIRAS 3), an Imprinted Tumor Suppressor Gene, Binds to Importins, and Blocks Nuclear Translocation of Stat3. Nature Precedings, 2008, , .	0.1	0
68	The Role of Angiogenesis, Growth Arrest and Autophagy in Human Ovarian Cancer Xenograft Models for Tumor Dormancy., 2014,, 99-109.		0